Modality
mAb
MOA
TNFi
Target
FcRn
Pathway
Neuroinflam
RAACC
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ Nov 2028
Phase 1Current
NCT06306178
2,073 pts·RA
2021-09→2027-06·Not yet recruiting
NCT04694193
190 pts·ACC
2018-05→2028-11·Completed
2,263 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-06-211.2y awayInterim· RA
2028-11-152.6y awayInterim· ACC
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Complet…
P1
Not yet…
Catalysts
Interim
2027-06-21 · 1.2y away
RA
Interim
2028-11-15 · 2.6y away
ACC
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06306178 | Phase 1 | RA | Not yet recr... | 2073 | DAS28 |
| NCT04694193 | Phase 1 | ACC | Completed | 190 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Rimatinib | Ventyx Bio | Phase 1 | CD20 |